Date: 2016-01-04
Type of information: Nomination
Compound:
Company: Global Blood Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 4, 2016, Global Blood Therapeutics, announced the appointment of Scott Morrison, who brings 35 years of financial experience helping life sciences companies excel from start-up, through initial product launch, to global expansion. Mr. Morrison served as Ernst & Young’s U.S. Life Sciences Leader since 2002 (retired December 2015). He has worked on hundreds of public and private financings, including more than 40 IPOs and 100 follow-on offerings and is considered a recognized expert in the M&A arena. Mr. Morrison served on the boards of the Bay Area Bioscience Center (BayBio), the Biotechnology Institute, the Biotechnology Industry Organization (BIO) ECS Board and the California Life Sciences Foundation. He has also co-authored several annual reports on the industry. He graduated from the University of California, Berkeley and is a Certified Public Accountant (inactive).
Financial terms:
Latest news:
